Cellectis S.A.
NASDAQ:CLLSBiotechnology
-$0.02 today
- Market cap
- $103.75M
- Beta
- 2.75
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.67
Volume 0.01M
Average 0.04M
CLLS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Cellectis S.A.NASDAQ: CLLS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $4.55M fell 7.7% year over year, behind the -2.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 10.7% from the prior quarter. Over 3 fiscal years it compounded at +3.0% a year.
Context
- Depreciation & amortization amounted to 27.6% of revenue in FY2025, down 20.2 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -7.7% toward the trailing-twelve-month pace of -2.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 20.12M USD
- Year-over-year change
- +1.4%
- 4-year CAGR
- +9.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.12M | +1.4% |
| FY2024 | 2024-12-31 | 19.84M | +7.1% |
| FY2023 | 2023-12-31 | 18.52M | +0.5% |
| FY2022 | 2022-12-31 | 18.44M | +30.2% |
| FY2021 | 2021-12-31 | 14.16M | — |
Depreciation & Amortization vs competitors
How CLLS compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -2.6% is the 7th highest of 9, against a peer median of +11.7%.
- Depreciation & amortization amounts to 28.9% of revenue for CLLS, versus a peer median of 96.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.68M USD | -2.6% | +3.0% | 28.9% | |
| LTM Mar 2026 | $3.75M USD | -7.8% | +14.7% | 97.6% | |
| LTM Mar 2026 | $3.14M USD | +14181.8% | -37.6% | — | |
| LTM Dec 2025 | CHF 2.5M CHF | +15.5% | +0.4% | 69.9% | |
| LTM Dec 2025 | $1.23M USD | — | +8.0% | — | |
| LTM Mar 2026 | $1.18M USD | +9.0% | -11.2% | 236.0% | |
| LTM Mar 2026 | $885K USD | — | -2.3% | 96.0% | |
| LTM Mar 2026 | $674K USD | +14.4% | +24.6% | — | |
| LTM Mar 2026 | $326K USD | +176.0% | — | — | |
| LTM Mar 2026 | $257.68K USD | +3.1% | -0.9% | — | |
| LTM Mar 2026 | $97.21K USD | -103.3% | -0.7% | 0.0% | |
| Peer median (excluding CLLS) | — | +11.7% | -0.7% | 96.0% | |
Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (96.75M) | (98.69M) | (116.84M) | (36.7M) | (67.8M) |
| Depreciation & Amortization | 14.16M | 18.44M | 18.52M | 19.84M | 20.12M |
| Deferred Income Tax | 0 | 87K | 371K | 0 | 0 |
| Stock-Based Compensation | 11.49M | 6.04M | 5.23M | 0 | 0 |
| Change in Working Capital | (12.3M) | (5.72M) | (3.99M) | 53.57M | (41.72M) |
| Accounts Receivables | (12.44M) | (8.99M) | 2.25M | (6.72M) | (4.44M) |
| Inventory | 215K | 0 | 0 | 0 | 0 |
| Accounts Payables | 177K | 3.25M | (6.31M) | 2.05M | (3.27M) |
| Other Working Capital | (252K) | 23K | 67K | 58.24M | (34.01M) |
| Other Non-Cash Items | (21.17M) | (7.6M) | 71.95M | (14.61M) | 49.26M |
| Operating Cash Flow | (104.56M) | (87.44M) | (24.75M) | 22.1M | (40.14M) |
| Capital Expenditures | (18.56M) | (2.44M) | (1.07M) | (2.58M) | (2.37M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (143K) | 0 | 0 | (162.48M) | (160.27M) |
| Sales of Investments | 15M | 126K | 0 | 63.69M | 134.24M |
| Other Investing Activities | 10.97M | (456K) | (14.44M) | 0 | 0 |
| Investing Cash Flow | 7.28M | (2.76M) | (15.51M) | (102.63M) | (29.58M) |
| Debt Repayment | (10.64M) | (6.6M) | 24.56M | 18.17M | (5.4M) |
| Common Stock Issued | 44.64M | 0 | 67.94M | 82.68M | 44.14K |
| Common Stock Repurchased | 0 | (569K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 13.53M | 8.32M | (9.64M) | (11.04M) | (10.85M) |
| Financing Cash Flow | 47.53M | 1.15M | 82.87M | 89.8M | (16.2M) |
| Effect of Forex Changes | (5.75M) | (3.36M) | 884K | (2.73M) | 6.24M |
| Net Change in Cash | (55.51M) | (92.42M) | 43.49M | 6.54M | (79.67M) |
| Free Cash Flow | (123.12M) | (89.89M) | (25.82M) | 19.52M | (42.5M) |
Cellectis S.A.
NASDAQ:CLLS
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.